Target intelligence / Profile preview

Amyloid beta protofibril (None)

Target
None
Molecular classification
Peptide aggregate, Protein aggregate
01

Overview

Amyloid beta (Aβ) protofibrils are intermediate, soluble aggregates formed during the self-assembly of amyloid beta peptides, particularly Aβ(1–40) and Aβ(1–42), which are central to the pathology of Alzheimer’s disease. These protofibrils represent a metastable state between smaller oligomers and mature amyloid fibrils. They are considered highly relevant as toxic species in neurodegenerative processes, disrupting cellular membrane integrity by inducing reactive oxygen species generation and lipid peroxidation. Compounds that stabilize or sequester Aβ peptides into non-toxic oligomeric or protofibrillar forms may have therapeutic potential if they prevent engagement with toxic pathways leading to cell damage or death.

Other names
Aβ protofibrilAmyloid beta oligomersAβ oligomers
02

Mechanism of action

N/A

03

Biological functions

NeurotoxicityMembrane disruptionReactive oxygen species generationLipid peroxidationAmyloid fibril formation intermediate
04

Disease associations

Alzheimer's diseaseNeurodegenerative disease
05

Safety considerations

Targeting protofibrils without affecting beneficial Aβ functionsPotential for off-target effectsEnsuring drugs do not promote formation of more toxic species
06

Biomarkers

Levels of Aβ protofibrils in cerebrospinal fluidPresence of Aβ protofibrils in brain imaging

Beyond the preview

Go deeper on Amyloid beta protofibril (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amyloid beta protofibril (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call